# Auranofin PK Following Oral Dose Administration

> **NCT02089048** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 15 (actual)

## Conditions studied

- Amoebiasis

## Interventions

- **DRUG:** Auranofin

## Key facts

- **NCT ID:** NCT02089048
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-02
- **Primary completion:** 2014-09-09
- **Final completion:** 2015-05-13
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089048, "Auranofin PK Following Oral Dose Administration". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02089048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*